VIA Pharmaceuticals IncOver The Counter Market:VIAP
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
VIA Pharmaceuticals Inc | 20.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Netmed Inc | 140.0 | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
FutureWorld Corp | 5.2K | 0.0x | --- |
FluoroPharma Medical Inc | 3.4K | 0.0x | --- |
Company Information
VIA Pharmaceuticals, Inc. (VIA) is a development-stage biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.
Contact Information
- Headquarters
- 750 Battery St Ste 330SAN FRANCISCO, CA, United States 94111-1525
- Phone
- 415-283-2200
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Douglass Given
- President, Chief Executive Officer, Director
- Lawrence Cohen
- Principal Financial Officer, Vice President, Controller
- Karen Wright
- Senior Vice President - Research and Development
- Rebecca Taub
- Independent Director
- Mark Bagnall
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.47 |
Book Value | $-0.90 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
